RheumNow Week in Review – 30 September 2016 Save

Dr. Jack Cush Reviews highlights in the news and journals from the past week on RheumNow.com:

1. Proteomic analysis of RA gut microbiome shows unique citrulline peptides - gut mucosa may contribute to ACPA in RA. http://buff.ly/2cVh4Cz
2. Indomethacin treatment of mice w/ premalignant lesions shows cancer slowing - PGE2 inhibition results in more CD8 Tcells and IFN http://buff.ly/2dvtLcF
3. Prime Therapeutics shows Xeljanz discontinuations at 30% by 6mos & 44% at 1 yr. 10% use it before MTX/other DMARDs https://t.co/PwqAzkiIij
4. Taiwan study of HIV population and risk of autoimmune disease showed higher risk for Sjögrens (SIR=1.64), psoriasis (2.05), SLE (2.59), AIHA (35.06), Uveitis (2.50) https://t.co/qsgODbKKxW
5. Yale study of Alopecia (areata or universalis) showed 32% of 66 pts improved with tofacitinib 5mg bid after 3 months. https://t.co/DBmnWEujiM
6. IL-6 inhibitor (PF-04236921) NOT effective in SLE;186 pts RCT- 3 doses same as placebo in SRI-4, BICLA responses https://t.co/xBc3D9ONH3
7. Scleroderma Renal Crisis review: 3-5 yrs after onset; acute rise in BP & creat, oliguria, 1/2 with thrombotic angiopathy https://t.co/KqSgJ9DiUl
8. EGPA (Churg-Strauss)157 pts:12y delay in Dx, severe asthma predates systemic symptoms by 12 yrs, asthma worse 3-6mo before Dx https://t.co/7Ab3nFnLjJ
9. Rates of Septic arthritis increased 43% in UK (5.5-->7.8/100k) over last 15yrs, especially in elderly >75. https://t.co/WLJ2J8QGtK
10. Serious infections in RA are related to disease activity. The risk with biologics is most likely in 1st 6mos of use. https://t.co/0tPxF1BrZo
11. RA pts (vs non RA) more likely to get Rx: GI Rxs, Abx, thyroid, tricyclics, asthma/inhaled steroids, PPI, HTN Rxs. https://t.co/aLMHoaunCH
12. 5 severe PSS patients getting transplants were Rx w/ immunosuppressives; showed improvement in skin & lung function… https://t.co/t1a9a0plgh
13. NSAIDs Pose a Dose-Related Risk for Heart Failure Hospitalizations
14. ICD-10 Grace Period Ends October 1st
15. Anti-Sclerostin Drug Prevents Vertebral Fractures in Post-Menopausal Osteoporosis 
16. FDA Approves New Amgen Biosimilar for Adalimumab - Amjevita (generically called adalimumab-atto) becomes the fourth biosimilar to be FDA approved 
17. FDA Approves Stelara for Crohn's Colitis  
18. Ilaris Gets FDA Approval for Rare Febrile Disorders